oxycodone + flurbiprofen axetil + dexamethasone

Oxycodone + flurbiprofen axetil + dexamethasone is a multimodal analgesic combination therapy developed by researchers at Beijing Tongren Hospital and Capital Medical University for the management of pain in cancer patients, particularly postoperative pain following oncological surgeries such as lung cancer resection. This regimen leverages three distinct mechanisms of action to achieve synergistic pain relief: oxycodone acts as a potent mu-opioid receptor agonist to modulate central pain perception; flurbiprofen axetil, an injectable prodrug of the NSAID flurbiprofen, inhibits cyclooxygenase (COX) enzymes to reduce peripheral inflammation and prostaglandin-mediated sensitization; and dexamethasone, a synthetic glucocorticoid, provides additional anti-inflammatory effects and helps mitigate postoperative nausea and vomiting (PONV). By combining these agents, the regimen aims to improve analgesic efficacy, reduce the total opioid requirement (opioid-sparing effect), and enhance patient recovery profiles.

Other names

oxycodone/flurbiprofen axetil/dexamethasone multimodal analgesia